Department of Laboratory Medicine and Pathology, Minneapolis Veteran Affairs Health Care System, Minneapolis, MN 55417, USA.
Department of Laboratory Medicine and Pathology, Minneapolis Veteran Affairs Health Care System, Minneapolis, MN 55417, USA.
Hum Pathol. 2018 Mar;73:102-107. doi: 10.1016/j.humpath.2017.09.010. Epub 2017 Sep 29.
Adenomatous hyperplasia of the rete testis (AHRT) is an uncommon abnormality first described by Nistal and Paniagua in 1988. Congenital and acquired forms of AHRT are recognized. We present a case of AHRT in a patient who underwent bilateral orchiectomy for penile carcinoma; he had received chemotherapy for Hodgkin lymphoma 18 years prior. Proposed causes for this disorder include developmental, hormonal, and paracrine induction by adjacent testicular tumors and exposure to chemicals, based on clinical contexts but without experimental support. We performed immunohistochemical studies using markers of cell cycle (cyclin D1, p16), proliferation (Ki-67), apoptosis (bcl2), senescence (γ-H2AX), and androgen receptors to try to provide scientific support for or refute existing hypotheses. Our results indicate that, in this case of acquired AHRT after chemotherapy, the process is neither adenomatous nor hyperplastic but rather represents abnormal accumulation of rete testis cells with acquired senescence.
睾丸网腺瘤样增生（AHRT）是一种不常见的异常，于 1988 年由 Nistal 和 Paniagua 首次描述。目前已经认识到先天性和获得性 AHRT。我们报告了一例因阴茎癌行双侧睾丸切除术的患者的 AHRT 病例，他在 18 年前因霍奇金淋巴瘤接受了化疗。根据临床背景提出了这种疾病的可能原因，包括发育、激素和旁分泌诱导，以及相邻睾丸肿瘤和接触化学物质，但是没有实验支持。我们使用细胞周期（cyclin D1、p16）、增殖（Ki-67）、凋亡（bcl2）、衰老（γ-H2AX）和雄激素受体的标志物进行免疫组织化学研究，试图为现有假说提供科学依据或反驳。我们的结果表明，在这种化疗后获得性 AHRT 的情况下，该过程既不是腺瘤性的也不是增生性的，而是代表获得性衰老的睾丸网细胞异常积聚。
